It has long been known that metabolites may contribute to drug action and toxicity, act as inhibitors of drug elimination, or displace the drug from plasma or from tissue binding sites. However, the quantitative importance of metabolites in drug therapy has not been well characterized. Classic examples of drugs that have pharmacologically important (active) metabolites include morphine as a metabolite of codeine, phenobarbital as a metabolite of primidone, enalaprilat as a metabolite of enalapril, and desipramine as a metabolite of imipramine.
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In some cases, metabolites may constitute a risk factor for drug toxicity. In recognition of this, the US Food and Drug Administration issued the so-called MIST (metabolites in safety testing) guidelines (http://www.fda.gov/ downloads/ Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm079266.pdf), which establish a strategy for toxicology evaluation of circulating metabolites. Emphasis is placed on metabolites that circulate in concentrations >10% of the parent drug concentration at steady state. The International Conference on Harmonisation M3 guideline recently issued by the European Medicines Agency, on the other hand, focuses on metabolites that circulate at 10% of total drug-related material. The International Conference on Harmonisation and MIST guidelines are, however, specific for toxicity testing and do not relate to the study of the metabolites as inhibitors of metabolic enzymes or as displacers of binding.
Although metabolites have received consistent attention with respect to their role in pharmacological action and in drug toxicity, their role in inhibitory drug-drug interactions (DDIs) has not been well characterized. This is perhaps due to the fact that there are no established examples of clinical interactions that are caused solely by an inhibitory metabolite in the absence of any inhibitory effect by the parent drug. Several clinically important inhibitors have recently been recognized to have circulating metabolites that have inhibitory effects. For example, hydroxyitraconazole as a metabolite of itraconazole, N-desmethyldiltiazem as a metabolite of diltiazem, and norfluoxetine as a metabolite of fluoxetine appear to contribute to in vivo DDIs. [1] [2] [3] [4] It is currently not known whether these three drugs are exceptions or whether they are examples of a more prevalent phenomenon of multiple inhibitors being responsible for a single interaction. In setting out to evaluate the role of inhibitory metabolites in clinically important DDIs, we recently determined that a majority (82%) of clinically used cytochrome P450 (CYP) inhibitors possess circulating metabolites, and that all known potent CYP inhibitors have circulating metabolites. 5 In this study, the exposures to metabolites after administration of the parent compound were quantitatively analyzed. The aim of this study was to determine articles the relative importance of circulating metabolites in clinical DDIs. The University of Washington Metabolism and Transport Drug Interaction Database was used to collect the relevant in vitro enzyme inhibition data and clinical interaction data, and in vivo interaction potential was analyzed in accordance with US Food and Drug Administration guidelines.
Results

Prevalence of circulating metabolites
The metabolite-to-parent area under the plasma concentrationtime curve (AUC) ratios were calculated for 72 of the 102 previously identified inhibitors 5 on the basis of the availability of data. Because some of the inhibitors have several circulating metabolites, this resulted in 120 data sets of AUC M /AUC P ratios (Figure 1) . Within these data, 37% of the metabolites had an AUC greater than that of the parent drug, and an additional 46% had an AUC that was between 10 and 100% of that of the parent drug. Only 17% of all the metabolites were determined to be insignificant in terms of their AUCs in relation to the AUC of the parent drug (AUC M /AUC P <0.1). Figure 1 depicts the distribution of the inhibitors based on metabolite-to-parent AUC ratio with steady-state and single-dose data. The individual metabolite-to-parent pairs and the AUC values used for the analysis are summarized in Supplementary Appendix 1 online (steady-state data) and Supplementary Appendix 2 online (single-dose data). Supplementary Appendix 3 online shows the list of circulating metabolites for which no pharmacokinetic characterization was available. When the data were analyzed separately for weak, moderate, and potent inhibitors, the distribution of AUC M / AUC P ratios was similar to that of all the inhibitors together.
Prediction of relative contributions of metabolites to in vivo DDIs
Quantitative predictions of the importance of metabolites in in vivo DDIs were done by calculating the IP M /IP P ratios (inhibitory potency of the metabolite as [I]/K i, over the inhibitory potency of The aUC M /aUC P ratios (y-axis) for all the inhibitor drugs referred to in supplementary Appendixes 1 and 2, with each bar representing a specific metabolite-parent pair. Blue bars refer to steady-state data and red bars to single-dose data. The percentages above the bars indicate the fractions of inhibitors in each group categorized by the values of the aUC M /aUC P ratio (aUC M / aUC P > 0.1; 0.1 < aUC M /aUC P < 1; aUC M /aUC P ≥ 1). (b) The distribution of aUC M /aUC P ratios for the inhibitor drugs for which in vivo drug-drug interaction data of clearance and aUC changes of marker substrates. The drugs were classified according to the system recommended by the US Food and Drug administration (http://www.fda.gov/cder/drug/drugInteractions/) as potent (>5-fold increase in aUC), moderate (>2-but <5-fold increase in aUC), or weak (>1.25-but <2-fold increase in aUC) inhibitors of the target enzyme. aUC, area under the plasma concentration-time curve; M, metabolite; P, parent.
articles the parent as [I]/K i ) for all inhibitors for which circulating concentrations of the metabolite and parent were available and for which in vitro K i values had been determined. Table 1 shows a summary of the calculated IP M /IP P ratios. The metabolites were predicted to be most significant in vivo inhibitors for 11 of the 21 (52%) inhibitor drugs analyzed, whereas five metabolites belonging to four inhibitors (19%) were predicted not to contribute to the in vivo interaction (IP M /IP P ratio <0.1). Notably, the two inhibitors that are commonly recognized to have inhibitory metabolites, itraconazole and fluoxetine, had IP M /IP P ratios <1. For three of the potent or moderate inhibitors analyzed, namely, amiodarone, amodiaquine, and bupropion, the IP M /IP P ratios ranged from 5 to 25, demonstrating that the metabolites are predicted to be the main contributors to interactions. On the other hand, omeprazole sulfone, quinidine N-oxide, and 3-hydroxy quinidine had IP M / IP P ratios <0.01, corresponding to a prediction of insignificant contribution to the in vivo interactions.
Role of circulating metabolites in risk analysis of inhibitory interactions
Given that metabolites were predicted to quantitatively contribute to selected in vivo DDIs, the effect of circulating metabolites on preclinical risk analysis of potential DDIs was determined. Only inhibitors for which in vivo interaction data with accepted probes articles were available, allowing establishment of in vivo interaction risk, were included in the analysis. The [I]/K i ratios were calculated for the inhibitors and metabolites for which sufficient data were available. Of the 11 inhibitor drugs included in the analysis, 6 (54%) were classified as "possible" or "likely" interactions on the basis of the parent drug's effect alone ( Table 2 ). Metabolites of 6 of the 11 compounds were qualitatively predicted to be associated with equal or greater risk of causing DDIs than the parent inhibitor. Five compounds-amiodarone, bupropion, ranolazine, sertraline, and venlafaxine-were classified as representing "remote risk" for in vivo interactions when only the effect of the parent drug was considered. Two of these in vivo inhibitors, amiodarone (CYP2C9) and sertraline (CYP3A4), were categorized as "possible risk" and one, bupropion (CYP2D6), as "likely risk" when inhibition by known circulating metabolites was also considered; the in vivo interactions caused by ranolazine (CYP3A4) and venlafaxine (CYP2D6) were not predicted with the available in vitro inhibition data. Figure 2 shows the correlation between in vitro risk assessment and the magnitude of in vivo DDIs when only the parent drug is considered and when parent and metabolites are analyzed together. As shown in Figure 2 , the moderate inhibitor amiodarone and the potent inhibitor bupropion were predicted to be in vivo inhibitors only when their metabolites were also included in the analyses.
It is important to note that, for sertraline, the interaction with CYP3A4 could be predicted when the metabolite effect was taken into account, whereas the CYP2D6 interaction could not.
Quantitative in vitro-to-in vivo extrapolation of DDIs
In vivo DDIs are commonly rationalized by the use of static or dynamic models that allow extrapolation of in vitro inhibition potency to in vivo interactions. The existence of circulating inhibitory metabolites could cause a significant underprediction of the existing interactions and, if metabolites are not accounted for, could lead to a poor understanding of the characteristics of specific interactions. In order to determine whether the presence of circulating metabolites leads to significant underpredictions in known, well-characterized DDIs, the effects of inhibitory metabolites in the accuracy of in vitro-to-in vivo predictions of interaction magnitude were tested using classic static prediction methods. Table 3 shows the predicted and observed interactions for the 10 inhibitors analyzed. Interactions were included in the analysis wherever in vivo data with a well-characterized probe were available and [I]/K i ratios could be calculated for both the parent drug and the metabolite. Both maximum plasma concentration (C max ) and average steady-state plasma concentration (C av ) were used in the analysis, and no apparent differences were observed between the predictions using these two values. This might be because, at steady state, there is minimum fluctuation in the inhibitor concentrations over the dosing interval, and therefore C max and C av values are similar. For amiodarone, bupropion, fluoxetine, and sulfinpyrazone, improved quantitative predictions of the in vivo interactions were obtained when metabolites were accounted for, whereas for the remaining six inhibitors, no significant differences in prediction accuracy were observed. The fact that, in 4 of the 10 inhibitors analyzed, quantitative predictions were possible only after accounting for the metabolites suggests that knowledge of circulating metabolites and their inhibitory potency should be obtained prior to quantitative modeling of the observed interaction.
DIscussIon
This study was aimed at determining the extent to which circulating metabolites contribute to in vivo DDIs in the context articles of preclinical risk assessment and development of quantitative methods of predicting in vivo DDIs. The analysis shows that a majority of the clinically important CYP inhibitors have metabolites that circulate at appreciable concentrations and that one-third of the known metabolites are more abundant in the circulation than the parent drug. However, the CYP inhibiting potency has been published only for some metabolites. It is possible that unpublished negative inhibition data that were not available for this analysis exist. The available data for known metabolites were evaluated to determine whether these metabolites would alter the preclinical risk assessment of known clinical CYP inhibitors. Surprisingly, for 3 of the 11 inhibitors evaluated, the risk assessment changed from "remote likelihood" of DDIs to "possible" or "likely" with the inclusion of metabolites in the analyses. This suggests that determination of K i values for quantitatively important metabolites can be useful when no interactions or only weak interactions are predicted with the parent drug. On the other hand, testing for inhibitory potential of metabolites might be of limited usefulness if the parent drug on its own has an identified risk in the "likely" category, given that the true magnitude of the in vivo interaction will be determined in specific in vivo DDI studies. Interestingly, all the compounds that were "missed" in the risk analysis (amiodarone, bupropion, ranolazine, sertraline, and venlafaxine) when only the data related to the parent inhibitor drug were included, had metabolites with IP M /IP P ratios >0.1, suggesting that the metabolites of these compounds may have a critical role in causing in vivo DDIs. On the other hand, omeprazole sulfone, quinidine N-oxide, and 3-hydroxy quinidine, which were predicted in the risk analysis to have only remote potential to cause DDIs, had IP M /IP P ratios <0.1.
A possible explanation for the incorrect assignment of risk for the ranolazine-simvastatin interaction could be the involvement of transporters such as P-glycoprotein in the in vivo interaction. Ranolazine has been shown to cause a 1.5-fold increase in in vivo digoxin concentrations, suggesting that it is a P-glycoprotein inhibitor (http://www.accessdata.fda.gov/drugsatfda_docs/ nda/2006/021526_s000_Ranexa.cfm). Given that simvastatin has been shown to be a P-glycoprotein substrate, 6 it is possible that the in vivo interaction is due to P-glycoprotein inhibition during simvastatin absorption. Although data for the other probes, inhibitors, and metabolites are not available, it is possible that transporter-mediated interactions contribute to the other underpredictions as well. In addition, metabolites may be sequestered in the hepatocytes, and consequently plasma concentrations may not accurately reflect the intracellular free inhibitor concentrations. Such sequestration is not accounted for in the current analysis. 
articles
A special consideration may be warranted in the case of compounds that are multi-CYP inhibitors in vitro. These compounds are typically analyzed using a rank-order approach. 7 Because inhibitor depletion prevents the formation of significant amounts of metabolites in in vitro inhibition assays, rank-order analyses in vitro are likely to reflect the potency of the parent drug. If metabolites do not follow the same rank order, or inhibit only a subset of the CYPs that the parent compound inhibits, the rank-order approach may fail. For the three multi-CYP inhibitors included in this analysis, the rank order for the metabolite was similar to that observed for the parent drug when reversible inhibition was considered, but the data set is not representative of the overall multi-CYP inhibitors.
The recently published MIST guidance recommends toxicology review of metabolites that circulate in concentrations >10% of those of their parent drugs. Although the MIST guidance does not address the role of metabolites in DDIs, our study analyzed the available data with reference to the 10% cutoff value of the MIST guidance. On the basis of the [I]/K i ratios of the metabolites in relation to the parent compounds, all the metabolites that were predicted to contribute to in vivo interactions (with the exception of 4-hydroxypropranolol) had AUCs >10% of those of their respective parent drugs at steady state. Interestingly, there was no correlation between the contributions of the metabolites to interactions (IP M /IP P ratio) and the relative abundance of the metabolites in plasma; this is because many metabolites were found to be more potent inhibitors than the parent drug even though they circulated at lower concentrations than the parent drug. Given these findings, the 10% cutoff value for AUC appears appropriate for inhibition testing of metabolites. On the basis of these analyses, predicting the [I]/K i ratio for abundant metabolites (as well as for the parent compound) can be helpful in the drug discovery and development process even when the parent compound is not inhibitory. This also requires that the methodology should be established for predicting [I] , not only for the parent drug but also for the metabolite.
The inhibitory metabolites included in this analysis may not be the sole circulating metabolites of the given inhibitor drug, but were the only ones with published in vitro inhibition data and in vivo AUC values. For example, 5-hydroxyomeprazole is more abundant than omeprazole sulfone in the circulation after the administration of omeprazole. However, no in vitro inhibition data were available for 5-hydroxyomeprazole, and therefore this metabolite could not be analyzed. Similarly, atorvastatin has several metabolites that circulate at concentrations similar to that of atorvastatin itself, but the inhibitory potencies of these metabolites have not been determined. On the other hand, although itraconazole has two other metabolites, keto-itraconazole and N-desalkyl-itraconazole, that inhibit CYP3A4 potently, their steady-state concentrations have not been determined. The existence of multiple inhibitory metabolites for a given drug would further increase the relative contributions of metabolites as a whole in comparison to the parent drug.
The role of inhibitory metabolites in quantitatively predicting the magnitude of DDIs may be less than would be expected from the abundance of the metabolites. In the analysis of quantitative predictions, inclusion of metabolites did not always improve the accuracy of the prediction, and the increase in average predictive accuracy was only modest. However, in the case of some of the inhibitors, significant improvement in predictions was observed. Given that data related to plasma and microsomal unbound fractions are not available for a majority of these compounds, the quantitative prediction may not accurately reflect the true relative importance of all of the metabolites analyzed. Despite this, the fact that so many inhibitors have circulating inhibitory metabolites may have implications for overall correlation analyses of in vitro-to-in vivo extrapolations because an accurate model should incorporate all inhibitory species.
In conclusion, these results suggest that metabolites or candidates for major circulating metabolites in vivo should be investigated, in addition to the parent drug for inhibition potential in vitro unless clinical interaction studies are already warranted because of the parent compound's inhibitory effect. Although the available data in the literature do not allow for comprehensive evaluation, these results suggest that circulating metabolites contribute to in vivo DDIs. Further studies are required for an in-depth understanding of their overall clinical significance.
MethoDs
Identification of the inhibitors and their metabolites.
We searched the University of Washington Metabolism and Transport Drug Interaction Database (MTDI database: http://www.druginteractioninfo.org) to identify known CYP inhibitors. All the inhibitors selected for analysis had to be drugs currently available in the US market; herbal products, combination therapies, and oral contraceptives were excluded from the analysis. The complete list of identified inhibitors and their CYP inhibition characteristics was previously published previously. 5 The AUC values for the parent inhibitor drugs and their metabolites were extracted from the MTDI database by searching for results of DDI studies in which the concentrations of the compounds as well as their metabolites were measured. If no data related to metabolites were available in the MTDI database, a PubMed search was conducted to extract data related to circulating metabolites. Finally, product labels and Micromedex were used as references for data related to circulating metabolites. For calculation of metabolite-to-parent AUC ratios, the following criteria were used:
1. The concentration levels of the metabolite and the parent drug were required to be from the same study, and complete AUCs (dosing interval at steady state or 0-infinity after single dose) for both had to be available. 2. Steady-state values for the parent drug and its metabolites were used if available. If steady-state pharmacokinetics data were not available, single-dose kinetics were accepted. The ratios between the AUCs of the metabolite and the parent were calculated either by using the steady-state dosing interval AUC or by using the AUC to infinity after a single dose. 3. For compounds for which data from multiple dosing levels were available, the highest AUC M /AUC P ratio was used.
All AUC values were converted to μmol·h/ml units using the molecular weight of the parent drug and the metabolite, before calculating the ratio between the AUCs of the metabolites and the respective parent drugs.
Determination of the magnitude of in vivo DDIs and of the potency of inhibition of parent drug and metabolites. The MTDI database was queried to retrieve all reported in vivo interactions (defined as resulting in a ≥20% increase in the AUC or decrease in clearance of the victim drug) for the inhibitors that were previously identified as having circulating articles metabolites. From the resulting list of in vivo interaction studies, the ones conducted with known marker substrates (http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ ucm072101.pdf) were retained for further analysis. All data related to in vivo AUC changes determined using marker substrates were extracted, and the change in the AUC of the marker of interest was recorded for analysis. The concentration levels of the inhibitor drug and its metabolites as measured in the interaction study were recorded if available. For studies that did not measure the plasma concentrations of the inhibitor drug and its metabolites, data related to the same dosing regimen was accessed from the literature in order to calculate steady-state C max and C av values for the inhibitor drug and its metabolites. If data pertaining to the inhibitor drug and its metabolites were not available at the dose level used in the in vivo interaction studies, the concentrations were dosenormalized for the purposes of the risk analysis.
The MTDI database was queried to extract the in vitro K i values for the identified metabolites and the parent inhibitor drugs. Inhibitor drugs or their metabolites that were known inactivators of a given enzyme in vitro were excluded from further analysis for that enzyme. In case there were multiple reversible K i values for the parent inhibitor or its metabolites, the K i value used in the analysis was selected according to the following criteria: (i) the metabolite and the parent drug had been tested in the same study against the same CYP and same probe; (ii) if data related to both metabolite and parent drug were not available in the same study, two different studies that had used the same probe were chosen; (iii) in the absence of both these categories of data, results were taken from two studies that had used the same microsomal protein concentration. For equivalent data, the study with the lowest microsomal protein concentration was used.
Relative importance of circulating metabolites. In order to predict the relative contributions of the metabolites in in vivo DDIs, the [I]/K i ratios were calculated for all inhibitors and metabolites for which there were sufficient in vitro data. The clinically relevant steady-state average total concentrations of the drug and its metabolites (measured in the same study and at the same dose level) were used as [I] , and the K i values were obtained as described above. The [I]/K i ratio was calculated for the metabolites and parent drugs separately, and the ratio between the [I]/K i of the metabolite and the relevant parent drug (IP M /IP P ) was calculated. Because the [I]/K i ratios for the metabolite (IP M ) and for the parent (IP P ) are indicative of their in vivo inhibitory potential (IP), the ratio of the two can be used as a predictor of the relative in vivo contribution of metabolites to CYP inhibition. The predicted contribution of the metabolites was classified as follows: (i) if the IP M /IP P ratio was ≤0.1, the metabolites were not predicted to contribute to in vivo interactions; (ii) if the IP M /IP P ratio was ≥1, the metabolite was predicted to be the main inhibitory species causing the in vivo interaction; and (iii) if 0.1 < IP M /IP P < 1, the parent drug was predicted to be the main inhibitor causing the DDI, with the metabolite also categorized as "likely" to make a contribution.
Risk analysis using data related to metabolites and parent drugs.
A risk analysis for inhibitory interactions was conducted in accordance with the US Food and Drug Administration guidance for testing parent drugs (http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm079266. pdf). Inhibitor drugs were included in this analysis only if there was availability of in vivo interaction data with a known probe. The steady-state concentrations of the parent inhibitor drug (total C max ) and the in vitro Quantitative prediction of in vivo DDIs. In vivo DDI data for 10 inhibitor drugs, obtained with a probe substrate having a known f mCYP (fraction metabolized via specific CYP), were used to estimate the role of metabolites in quantitative in vitro-to-in vivo extrapolations of inhibitory interactions. In vivo studies were included in the quantitative analysis only if they had been conducted with a reliable probe with a defined f m (fraction metabolized) and if the C max and C av were available in the DDI study or in another study with a similar dosing regimen. If several DDI studies were available, the study with the highest AUC change was selected so as to consider the hypothetical worst-case scenario. The total C max and C av values for the inhibitor drug as well as for its metabolites were used in the predictions as [I] . 
